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A b s t r a c t
Traditional methods of describing and classifying neurodegenerative disease are based on the clinico-pathological 
concept supported by molecular pathological studies and defined by ‘consensus criteria’. Disease heterogeneity, 
overlap between disorders, and the presence of multiple co-pathologies, however, have questioned the validity and 
status of many traditional disorders. If cases of neurodegenerative disease are not easily classifiable into distinct 
entities, but more continuously distributed, then a new descriptive framework may be required. This review proposes 
that there are four key neuropathological features of neurodegenerative disease (the ‘primary determinants’) that 
could be used to provide such a  framework, viz., the anatomical pathways affected by the disease (‘anatomy’), 
the cell populations affected (‘cells’), the molecular pathology of ‘signature’ pathological lesions (‘molecules’), and 
the morphological types of neurodegeneration (‘morphology’). This review first discusses the limitations of existing 
classificatory systems and second provides evidence that the four primary determinants could be used as axes to 
define all cases of neurodegenerative disease. To illustrate the methodology, the primary determinants were applied 
to the study of a group of closely related tauopathy cases and to heterogeneity within frontotemporal lobar degen-
eration with TDP-43 proteinopathy (FTLD-TDP).
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Introduction
Traditional methods of describing and classify-
ing cases of neurodegenerative disease are based 
on the original clinico-pathological concept, viz., 
a distinct clinical profile in combination with ‘signa-
ture’ pathological lesions. This system was used to 
describe the first cases of Alzheimer’s disease (AD) 
[2], Pick’s disease (PiD) [139], dementia with Lewy 
bodies (DLB) [107], and Creutzfeldt-Jakob disease 
(CJD) [44,88]. Subsequently, these original descrip-
tions were refined and modified by molecular stud-
ies which resulted in the discovery of disease-spe-
cific antibodies and enabled the molecular signature 
of brain lesions to be established [20,59]. Ultima- 
tely, ‘consensus criteria’ have been established for 
the majority of disorders, e.g., AD [120,125,133,162], 
DLB [120], multiple system atrophy (MSA) [71,72], 
and progressive supranuclear palsy (PSP) [108,109], 
representing the coordinated views of experts in 
the field regarding the most important clinical and 
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pathological features useful in diagnosis. As a result, 
neurodegenerative disorders have continued to be 
regarded as more or less distinct ‘entities’, neuro-
pathologically defined by signature pathological 
lesions, and characterised by a  specific molecular 
pathology [20,59]. 
Recent research, however, has revealed consider-
able heterogeneity within existing disorders [15,22], 
overlap between closely related entities [19,55,63,76], 
and the co-occurrence in individual cases of two or 
more co-pathologies [19,93,172]. Hence, in a recent 
comparative study of 1032 cases representing ten 
different disorders, 361 cases, approximately 35% 
of the sample, were excluded largely as a  result of 
multiple pathology [25]. Not only do these exclusions 
ignore a large quantity of data, a bias is also created 
in favour of ‘typical’ or ‘pure’ examples of a  disor-
der, thus ignoring potential intermediate, overlap, or 
multiple pathology cases. As a consequence, a recon-
sideration of existing disease entities and a  new 
descriptive framework which can accommodate over-
lap and heterogeneity may be necessary [8,19,54,62, 
128,137]. 
An alternative method of describing cases of 
neurodegenerative disease is to use a  geometrical 
system based on ‘ordination’, i.e., by arranging indi-
vidual cases with reference to a co-ordinate frame so 
that their similarities and differences can be spatial-
ly represented [8,15,22,140]. In such a system, there 
may be no attempt to name a disorder or to classify 
cases into any pre-existing groups, but only to plot 
individual cases with reference to the co-ordinate 
frame. Location of a case would reveal its similari-
ties and differences to other cases, and proximity to 
similar cases may reveal underlying common patho-
logical mechanisms. To define the axes of such a co- 
ordinate frame, however, would require quantitative 
measures of a range of neuropathological variables.
This review proposes that there are four key 
features of neurodegenerative disease (the ‘prima-
ry determinants’) which could be used to provide 
such a  descriptive framework, viz., the anatomical 
pathways affected by the disease (‘anatomy’), the 
cell populations affected (‘cells’), the major molecu-
lar pathology of the ‘signature’ pathological lesions 
(‘molecules’), and the morphological types of neu-
rodegeneration (‘morphology’). Hence, this review 
discusses: (1) limitations of existing classificatory 
systems, (2) evidence that the four primary deter-
minants could provide a description of cases of neu-
rodegenerative disease, (3) whether the four deter-
minants are ‘independent’ variables, (4) whether 
the four determinants should be differentially 
weighted, and (5) describes the application of the 
method to the study of a  group of closely-related 
tauopathy cases and heterogeneity within fronto-
temporal lobar degeneration with TDP-43 proteino- 
pathy (FTLD-TDP) [22]. 
Limitations of existing classifications
Several studies have questioned whether neuro-
degenerative diseases are distinct or whether indi-
vidual cases represent points in a  ‘continuum’ of 
neuropathological change [8,19,20]. Hence, exten-
sive overlap was observed between cases of AD and 
Parkinson’s disease (PD), interpreted as the action 
of common pathogenic mechanisms within vulnera-
ble neuronal populations [137]. The authors argued 
that currently defined disease entities failed to deal 
with disease overlap and that a  new classification 
should be considered [137]. In addition, Forstl [62] 
argued that the traditional clinico-pathological con-
cept often accommodates genetically and clinically 
diverse conditions within the same group and there-
fore may have outlived its usefulness. The frequent 
use by authors of such terms as ‘complex syndrome’, 
‘spectrum of disorders’, ‘multiple pathologies’, or 
even ‘continuum’ testifies to the extent to which 
boundaries between different disorders are more 
indistinct than previously thought [8,38,68,160]. 
Central to the argument of how neurodegenera-
tive disease should be classified has been the status 
of AD [101,118]. Alzheimer’s disease is heterogeneous 
[145] and can be divided into clinically relevant sub-
groups such as sporadic AD (SAD), tangle only AD, 
and the various genetic subtypes of familial AD (FAD), 
but only one subgroup actually corresponds to the 
disease originally described by Alzheimer [169]. In 
addition, a number of descriptive terms are used to 
describe AD co-pathology, e.g., AD neuropathological 
change (ADNC), and neurofibrillary tangle (NFT)-only 
change in medial temporal lobe (NFT-MTL). Defining 
exact criteria for AD has always been difficult due 
to phenotypic heterogeneity, the absence of specif-
ic markers, and overlap of pathology with cognitive-
ly normal brain and related disorders [7,90]. Hence, 
the term ‘AD’ may describe disease subgroups with 
markedly different characteristics, and it has been 
suggested that the looser term ‘Alzheimer syndrome’ 
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could be used or the term ‘AD’ dispensed with alto-
gether [169]. If AD was to disappear as an entity, it 
would have significant implications for the status of 
many closely related disorders such as argyrophilic 
grain disease (AGD) [32,163,178], vascular dementia 
(VD) [95,106], and DLB [120].
The status of many other classically defined dis-
orders has been equally controversial. Pick’s disease 
[139], for example, is defined pathologically by the 
presence of tau-immunoreactive Pick bodies (PB) and 
abnormally enlarged neurons (‘Pick cells’), but many 
cases of clinically typical PiD are at variance with 
these classic neuropathological features [98], e.g., 
some clinically typical PiD cases may lack PB [83]. 
Moreover, there is no convincing evidence linking 
the clinical symptoms of PiD with its histology, a chal-
lenge to the original clinico-pathological concept [60]. 
Subsequently, PiD became subsumed within the con-
cept of ‘frontotemporal dementia’ (FTD) [87], but this 
classification also resulted in a heterogeneous group 
of disorders with considerable overlap between its 
constituent members [19]. Subsequent genetic and 
molecular studies have led to considerable changes 
in the classification and nomenclature within FTD 
and its neuropathological variants, viz. fronto-tempo-
ral lobar degeneration (FTLD) [37,164]. Clinical vari-
ants of FTD include the behavioural variant (bvFTD), 
language variants, e.g., semantic dementia (SD) and 
primary progressive aphasia (PPA), and motor vari-
ants such as corticobasal syndrome (CBS) and motor 
neuron disease (MND). In addition, pathological 
variants of FTLD include those with tau, transactive 
response (TAR) DNA-binding protein of 43 kDa (TDP-43), 
and fused in sarcoma (FUS)-immunoreactive inclu-
sions [37].
Discrimination between different FTLD entities is 
often only possible using neuropathological criteria, 
the majority of which are based on the morphology 
and molecular composition of ‘signature’ patholog-
ical inclusions such as neuronal cytoplasmic inclu-
sions (NCI), neuronal intranuclear inclusions (NII), 
and glial inclusions (GI), the latter including oligoden-
droglial inclusions (‘coiled bodies’), tufted astrocytes 
(TA), astrocytic tangles (AT), and astrocytic ‘plaques’ 
(AP) [130]. Nevertheless, the clinical features of FTD 
may not predict their pathology, and neuropatholog-
ical features alone cannot establish a  diagnosis of 
FTD. In addition, studies have questioned whether 
some members should even be classified within FTD. 
Hence, corticobasal degeneration (CBD) is a predo-
minantly extrapyramidal motor disorder in which 
there is poor correlation between neuropathology 
and clinical syndrome [119]. In addition, there are 
FTD cases that exhibit a frontal lobe type of demen-
tia but accompanied by a typical MND-type pathol-
ogy not typical of any currently described FTD entity 
[30]. Consequently, FTD may define a group of cas-
es, loosely united by clinical presentation, but with 
heterogeneous pathologies and therefore not easily 
classifiable according to clinico-pathological or any 
other criteria [77,79,99].
Similar problems can be observed within CJD, 
which in the past was regarded as a doubtful dis-
ease entity [100]. The original CJD concept [44,88] 
was subsequently discarded in favour of the term 
‘prion disease’ [1,41], but there still remain problems 
such as overlap between CJD and other disorders, 
most notably with AD [19,20,76]. In addition, the 
prion-like behaviour of such pathological proteins as 
tau and a-synuclein [74,155] further blurs the dis-
tinction between classic prion diseases, tauopathies, 
and synucleinopathies.
The four primary determinants 
This review proposes four key features, viz. the 
‘primary determinants’, to describe the neuropa-
thology of neurodegenerative disease: (1) anatom-
ical pathways affected by the disease (‘anatomy’), 
(2) cell types affected (‘cells’), (3) primary molecular 
pathology of ‘signature’ pathological lesions (‘mole-
cules’), and (4) morphological types of neurodegen-
eration (‘morphology’). How currently defined disor-
ders may be related to these variables is shown in 
Table I.
Anatomy
One of the first demonstrations that a neurode-
generative disease was related to the breakdown of 
specific anatomical pathways was in AD [45,136]. 
Hence, a  major feature of the pathology of AD is 
the disruption of afferent and efferent connections 
between the hippocampal formation and the rest of 
the brain [45]. Alzheimer’s disease pathology may 
initially affect the temporal pole, especially the ento-
rhinal cortex (EC), before spreading to the posterior 
parahippocampal gyrus (PHG) and then in a stepwise 
fashion to the hippocampus and association cortex, 
leaving primary sensory areas unimpaired until lat-
er in the disease [31,58,91,136]. The pathology may 
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then spread among cortical gyri and to subcortical 
regions via cortico-cortical and cortical-subcortical 
pathways respectively [5,45,136]. This hypothesis 
is supported by studies of the spatial patterns of 
SP and NFT [6,13] and of transgenic mice, in which 
there is selective disruption of cortico-cortical path-
ways [47]. Furthermore, this pattern of neurodegen-
eration correlates with specific neurotransmitter 
deficits, e.g., acetylcholinesterase-immunoreactive 
neurites are present at the periphery of SP, which 
could represent the degeneration of ascending and 
cortical cholinergic pathways [157]. 
Although many authors continue to argue that AD 
is a  distinct entity [118], it is highly heterogeneous 
[42,61], and cases exhibit considerable neuropatho-
logical variation [15,19]. Variation in the anatomical 
spread of disease from its origin in the MTL could 
account for many of these differences [15,33,45]. Con-
sequently, there may be a close relationship between 
the distribution of the pathology and the clinical fea-
tures of individual patients [67]. For example, MTL 
areas are relatively spared in aphasic cases of AD, 
while more severe occipito-parietal degeneration, also 
termed posterior cortical atrophy (PCA), is often asso-
ciated with visual-spatial deficits at presentation [67].
The second commonest form of dementia is DLB, 
accounting for up to a  quarter of all cases [120]. 
An essential feature of the neuropathological diag-
nosis of DLB is the presence of LB in the cerebral 
cortex and/or brain stem. Nevertheless, DLB exists 
in a  variety of forms including neocortical, limbic 
[144], cerebral, and brainstem types, the neocortical 
subtype being the most common [85]. Many cases 
of DLB also exhibit ADNC [48,70,78], and therefore 
each pathological subtype of DLB can be divided 
into a ‘pure’ or ‘mixed’ form based on the degree of 
AD co-pathology [85]. Some studies have suggested 
anatomical differences in the pathways affected in 
AD and DLB. Brain glucose metabolism studies, for 
example, indicate that hypometabolism of the pri-
mary visual cortex (area V1) is more marked in DLB, 
whereas reductions in the posterior/temporal cortex, 
posterior cingulate gyrus, and frontal cortex occur in 
both AD and DLB [122]. Studies of regional cerebral 
blood flow (rCBF) report similar results, i.e., occipital 
hyperperfusion may be more frequent in DLB [110]. 
Table I. Description of the major neurodegenerative diseases according to the four primary determinants
Primary determinants
Disorder Anatomy Cells Molecules Morphology
AD GC, L N Aβ, 3R/4R tau SP, NFT
AGD L N, A, O 4R tau P-NFT, NT, GR, EN, V
CBD FT, M, SC N, A 4R tau NCI
CJD GC N PrPsc SP, V
DLB L, C N a-synuclein LB, NT, EN
FTD-MND MC, SC N, O tau NCI, GI
FTLD-TDP FT N, O TDP-43 NCI, GI, V
MSA SC O, N a-synuclein GCI
NIFID FT, L, SC N, O FUS NCI, GI
PD-Dem L, MC, SC N a-synuclein LB, LT, LG
PiD FT N 3R tau PB, PC
PSP SC N, A 4R tau NFT, GI, AP
Disorders: AD – Alzheimer’s disease, AGD – argyrophilic grain disease, CBD – corticobasal degeneration, CJD – Creutzfeldt-Jakob disease, DLB – dementia with 
Lewy bodies, FTDP-17 – fronto-temporal dementia and parkinsonism linked to chromosome 17, FTD-MND – motor neuron disease with dementia, MND – motor 
neuron disease, MSA – multiple system atrophy, NIFID – neuronal intermediate filament inclusion disease, PiD – Pick’s disease, PD – Parkinson’s disease, PSP 
– progressive supranuclear palsy; Anatomy: GC – general cortical, L – limbic, FT – frontotemporal, SC – subcortical; Cells: N – neurons, A – astrocytes, O – oligo-
dendrocytes; Molecules: Aβ – β-amyloid, PrPsc – disease form of prion protein, FUS – fused in sarcoma, TDP-43 – transactive response (TAR) DNA-binding protein 
of 43 kDa; Degeneration: AP – astrocytic plaque, SP – senile plaques, NCI – neuronal cytoplasmic inclusions, P-NFT – pre-tangles, NFT – neurofibrillary tangles, 
NT – neuropil threads, GCI – glial cytoplasmic inclusions, GR – grains, EN – abnormally enlarged neurons, LB – Lewy bodies, LT – Lewy neurites, LG – Lewy grains, 
PB – Pick bodies, PC – Pick cells, V – vacuolation
93Folia Neuropathologica 2016; 54/2
Can neurodegenerative disease be defined by four ‘primary determinants’: anatomy, cells, molecules, and morphology?
The pattern of temporal lobe atrophy may also differ 
between AD and DLB, with less hippocampal atro-
phy in DLB, which could explain the preservation of 
memory function in DLB [26].
In FTLD, which accounts for approximately 20% 
of all pre-senile cases of dementia [159], the patho-
logical changes are usually more circumscribed, 
affecting primarily frontal and temporal lobes [156]. 
Nevertheless, there is often selective anatomical 
degeneration within this group. For example, in FTLD 
with transactive response (TAR) DNA-binding protein 
of 43 kDa (TDP-43)-immunoreactive inclusions, atro-
phy of the frontal lobe and temporal pole is seen in 
97% of cases, but the hippocampus and subcortical 
areas are less affected [11,22,69]. In FTD and par-
kinsonism linked to chromosome 17 (FTDP-17) and 
CBD, however, degeneration largely affects the glo-
bus pallidus and substantia nigra and is accompa-
nied by pathological changes in the cerebral cortex 
and subcortical areas [143]. In MND, cortical pathol-
ogy is even more restricted to the motor cortex, 
although the brain stem and spinal cord may also 
be affected [29].
A  further group of disorders exhibit a predomi-
nantly subcortical pathology including MSA, PD lack-
ing dementia, and PSP. Hence in MSA, the substan-
tia nigra, striatum, inferior olivary nucleus, pontine 
nuclei, and cerebellum are affected [18,49,105]. In 
some cases, there may be progressive cerebral atro-
phy affecting the frontal lobes [103] and the motor/
premotor areas [168], the limbic system also being 
affected, principally in longer duration cases [138]. 
Although MSA is regarded as a  single entity, two 
main subtypes are now recognized [72], viz., the cer-
ebellar subtype (MSA-C) and parkinsonian subtype 
(MSA-P). The most consistent clinical syndrome, 
however, is parkinsonism, followed by cerebellar 
ataxia, and pyramidal tract signs [171]. Similarly, the 
anatomical distribution of pathological changes in 
PD is largely subcortical but with two clinical sub-
types, viz., an ‘akinetic-rigid’ form with cell losses in 
the ventrolateral substantia nigra and related motor 
systems and a ‘tremor-dominant’ form with cell loss-
es in the medial substantia nigra [89]. In addition, in 
PD with dementia (PD-Dem), which may be indistin-
guishable from DLB [28], there is spread of pathol-
ogy to affect the cortical regions and hippocampus 
[24]. Progressive supranuclear palsy exhibits a more 
restricted form of subcortical degeneration, often 
sparing the cerebral cortex entirely [113]. Two clin-
ical phenotypes have been identified, viz., Richard-
son’s syndrome (RS) and PSP-parkinsonism (PSP-P), 
the two subtypes varying in disease duration and in 
tau isoforms [173]. In addition, there is loss of cho-
linergic innervation to the thalamus and cerebral 
cortex in PD, but only to the thalamus in PSP [153].
Cells
The developing pathology of neurodegenerative 
disease may target specific cell populations. In AD, 
for example, it is the larger cortical pyramidal cells 
that are most vulnerable, smaller neurons being 
more resistant [80]. In addition, labelling of damaged 
neurons in AD is most conspicuous in lamina III of 
the cerebral cortex early in the disease but becomes 
more widespread as the pathology progresses [165]. 
This observation suggests a specific loss of cortico- 
cortical connections in AD [136], many of which use 
glutamate as neurotransmitter. The disease may 
then spread in either an orthograde or retrograde 
direction [45], gradually involving other neuronal 
types and eventually glial cells. In AD there is also 
loss of neurons which express the 75 kD neurotro- 
phic receptor p75NIR [174] which preferentially 
binds β-amyloid (Aβ), and hence cells that under-
go apoptosis could be mediated by this reaction. By 
contrast, cultured hippocampal neurons immunore-
active to the calcium-binding protein calretinin are 
more resistant to degeneration associated with Aβ 
[142]. Moreover in FTLD, glutamate-immunoreactive 
pyramidal cells as well as calbindin D-28 g-amino-
butyric acid (GABA) neurons are lost but parvalbu-
min-immunoreactive cells preserved [57], consistent 
with loss of the cortico-cortical connections in FTLD. 
A  distinctive pattern of hippocampal pathology 
is present in CJD involving selective vulnerability of 
GABA neurons [75]. Hence, parvalbumin-immunore-
active neurons are severely depleted while calbindin- 
immunoreactive cells, which represent an early loss of 
inhibitory neurons, are largely preserved [75].
In FTLD, GI can be observed in oligodendroglial 
cells in the hippocampus, PHG, and amygdala [134]. 
In addition, a fundamental cytoskeletal alteration of 
oligodendrocytes occurs in MSA [18,50,170] resulting 
in the formation of characteristic ‘glial cytoplasmic 
inclusions’ (GCI) [135] which can be observed in the 
substantia nigra, striatum, inferior olivary nucleus, 
pontine nuclei, and cerebellum [105]. A close associ-
ation between GCI and microtubules has also been 
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demonstrated [129], aberrant or ectopic expression 
of cdk5 and MAPK leading to abnormal phosphory-
lation of microtubule cytoskeletal proteins and the 
formation of inclusions. In MSA cases with frontal 
lobe atrophy [103], there are cell losses in laminae 
V/VI of the cerebral cortex, and GCI are often found 
in white matter. In addition, inclusions are found 
in the granule cell layer of the dentate gyrus and 
pre-frontal cortex and ‘dot-like’ structures or grains 
in the PHG [4]. The GCI may represent a pathological 
change synchronous with or preceding that of neu-
ronal loss in MSA [84]. In addition, TA [82,102,175] 
are present in the motor cortex and striatum in 
PSP [51]. Neurons affected in PSP also appear to be 
functionally related, NFT occurring in interconnect-
ed extrapyramidal and oculomotor structures [151]. 
The presence of astrocytic pathology is regarded 
as a diagnostic feature of PSP [82] which may dis-
tinguish the disorder from the closely related CBD 
[81,109].
Molecules
The molecular pathology of ‘signature’ patho-
logical lesions has played a highly significant role in 
diagnosis, the identification of new disease entities, 
and the development of theories of pathogenesis 
[20,59]. Studies of pathological lesions, however, 
reveal considerable molecular diversity [20]. In AD, 
for example, Aβ exists in several forms, the most 
common being Aβ42/43, found largely in SP, whereas 
the more soluble Aβ40 is also found in association 
with blood vessels [121,146] and may develop lat-
er in the disease [46]. In addition, Aβ deposits may 
be associated with a variety of additional molecular 
constituents [20] including apolipoprotein E (Apo E) 
[176], a-antichymotrypsin, sulphated glycosamino-
glycans, and complement factors [166]. Aβ-immu-
noreactive deposits also occur in DLB, but the ratio 
between the isoforms may differ from AD. In DLB, 
the predominant form of Aβ is Aβ42/43, as in AD, but 
the level of Aβ40 is reduced compared with AD [117]. 
The majority of disorders have either tau- or 
a-synuclein-immunoreactive pathology. Within the 
tauopathies, PiD is characterised by tau with three 
microtubule repeats (3R tau), while PSP and CBD 
are composed of four-repeat (4R) tau [50,127]. Cel-
lular inclusions in these disorders, however, are also 
associated with additional molecular constituents. 
Hence, PB in PiD are immunoreactive to ubiquitin 
and Alz-50 [111] and in the synucleinopathy DLB 
[27], LB are also reactive for intermediate filaments 
(IF) [65], neurofilament (NF) proteins [66], cyclin 
dependent kinase-5 [34], a-B crystallin [112], and 
polyubiquitinated chains [86]. Furthermore, aggre-
gates of abnormal intermediate filaments (IF) immu-
noreactive for a-internexin have been identified as 
a component of inclusions in neuronal intermediate 
filament inclusion disease (NIFID), a rare subtype of 
FTLD [10,30,36,92]. Subsequently, ‘fused in sarcoma’ 
(FUS) protein was identified as a  major pathologi-
cal protein in this disorder [23,132,177]. In addition, 
a significant number of cases of FTLD are linked to 
the product of the transcriptional repressor gene 
(TARDP), viz. TDP-43 [131], suggesting that these 
diseases may form another molecular group, viz., the 
TDP-43 proteinopathies.
Morphology
There are six main types of morphological degen-
eration observed in neurodegenerative disease. 
First, extracellular protein deposits are deposited in 
the neuropil e.g., Aβ in AD [73] or the disease form 
of prion protein (PrPsc) in CJD [152]. Second, intra-
cellular protein aggregates develop as inclusions 
in cell bodies, nuclei, and the processes of neurons 
and glial cells. These include the various types of 
NCI, including NFT in AD, LB in PD and DLB [120], 
PB in PiD [111], and tau-reactive neurons in CBD 
[81]. In addition, GI, including the GCI characteristic 
of MSA [135], occur in a variety of disorders includ-
ing FTLD-TDP, AGD, and CBD. Third, some disorders 
exhibit extensive neuropil threads (NT) or dystrophic 
neurites (DN) in specific brain regions such as in 
FTLD-TDP [22] and PD-Dem [24,149]. Fourth, disor-
ders such as PD-Dem also possess Lewy grains (LG) 
which are a-synuclein-immunoreactive and which 
resemble the tau-reactive argyrophilic grains (AG) 
commonly observed in AGD [32,163,178], AD [148], 
and elderly, cognitively normal brains [52,94]. 
Fifth, abnormally enlarged neurons (EN), defined 
as having an irregularly enlarged or swollen cell body 
in which the largest diameter of the perikarya is at 
least three times the nuclear diameter [9], are a com-
mon feature of many disorders including AD [64], 
PiD, CBD, and AGD [163]. Enlarged neurons are also 
present in CJD, especially in cases with severe white 
matter degeneration [17,96,104]. In PSP, however, 
EN are less numerous and where present confined to 
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limbic regions [124,167]. There are also different types 
of EN. Hence, in PiD and CBD [14,16], there is uniform 
swelling of the neuronal perikaryon resulting in the 
characteristic ‘ballooned’ neurons, these cells being 
referred to as either Pick cells (PC) in PiD or ballooned 
neurons (BN) in CBD [126]. In addition, there are swol-
len achromatic neurons (SAN) in which the cell body 
is more irregularly enlarged, the Nissl substance uni-
formly pale, powdery, and eosinophilic, and the cell 
nucleus displaced to the cell margin [113]. Finally, 
there are swollen cells which occur in inherited neu-
rovisceral disorders such as Niemann-Pick disease 
type-C in which swelling of the cell is associated with 
abnormalities in lipid storage [35,53]. Hence, EN in 
neurodegenerative disease lack specificity to any par-
ticular disease [64] but may indicate particular types 
of pathological change. Ballooned neurons occur after 
infarction and could represent an attempt at regener-
ation following axonal damage [3]. Enlarged neurons 
could also be a stress response since many swollen 
neurons are immunoreactive to a-B-crystallin induced 
by neuronal stress and which may have a protective 
function [123]. In addition, peripheral nerve transec-
tion, which separates nerve cells from their targets, 
may also lead to EN [141].
Sixth, significant vacuolation is a feature of many 
disorders, most notably CJD (‘spongiform change’) 
[152], but also to varying degrees AD, DLB, and FTLD, 
the latter often present as microvacuolation in super-
ficial cortical laminae [22]. In the sporadic subtype of 
CJD (sCJD), clustering of vacuoles occurs in associa-
tion with either neuronal perikarya or PrPsc deposits 
[17], while in the cerebellum of the variant subtype of 
CJD (vCJD), clusters of vacuoles in the molecular layer 
are negatively correlated with surviving Purkinje cells 
[21]. Hence, the degree of vacuolation could be an 
indication of the extent of neuronal loss in a region.
Independence of primary determinants
An important consideration is whether the four 
primary determinants are independent variables. If 
variables are inter-correlated, however, degeneration 
of a specific anatomical pathway may predict cell type 
affected, molecular pathology, or type of neurodegen-
eration. If this hypothesis is correct, then only certain 
combinations of anatomy, cells, molecules, and mor-
phology would define neurodegenerative disease. 
Hence, in AD, which has tau-immunoreactive NFT, LB 
may also be present, and there is a  strong correla-
tion between the presence of cortical a-synuclein-im-
munoreactive LB and degeneration of the substantia 
nigra [97]. In addition, in FAD linked to the APP717 
mutation, extrapyramidal features were present in all 
members of a single family and LB were present in 
a proportion of individuals [147]. Moreover, cortical LB 
in DLB are composed of intermediate filaments (IF) 
and a granular matrix, while brain stem LB have an 
electron-dense core and radially oriented filaments 
[65]. These results suggest that it is degeneration 
of a  specific anatomical pathway, e.g., the extrapy-
ramidal system, that could determine the molecular 
pathology, e.g., in this case, a-synuclein-immunore-
active LB. However, there is no specific relationship 
between grains (GR) and molecular pathology, GR 
being a-synuclein- or tau-immunoreactive in PD-Dem 
[149] and AGD [32,163,178] respectively. 
In AD, cortical and subcortical NFT are composed 
of morphologically similar paired helical filaments 
(PHF), but cortical and subcortical PHF have a differ-
ent molecular composition [161]. In addition, within 
the tauopathies, diseases may have morphological-
ly similar tau-immunoreactive inclusions [56] but 
exhibit regional differences in distribution, espe-
cially in PSP, PD and CBD, which could be associat-
ed with different types of tau abnormality. Further-
more, in Niemann-Pick disease, the clinical spectrum 
of the disease is heterogeneous, rapid progression 
being associated with axonal spheroids and slow 
progression with NFT and neuronal dystrophy [158]. 
The NFT have a similar composition to those of AD 
but a different morphology reflecting their regional 
origin. In addition, frontal lobe atrophy could occur 
in both PSP and DLB associated with either NFT or 
LB respectively [43]. Differences in the neuronal pop-
ulation affected in the frontal cortex or in patient 
genotype could account for these differences. Posi-
tive correlations have also been observed among the 
densities of LB, LN, and LG in PD-Dem, suggesting 
that they could result from degeneration of the same 
neurons, LB aggregating in cell bodies and LN and LG 
in adjacent neurites and synapses respectively [24].
Studies that directly correlate a molecular pathol-
ogy with loss of a specific cell type are rare. Howev-
er, McKenzie et al. [115] found that specific areas of 
MTL secreted large quantities of amyloid precursor 
protein (APP), and that more APP-immunoreactive 
neurons were found in these areas in head injury 
patients, which could explain the high density of SP 
in the temporal lobe in AD [12] and the subsequent 
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spread of pathology [45]. In PSP, tau mRNA isoforms 
containing 4R tau are increased in the brainstem but 
not in the frontal cortex or cerebellum, which could 
predict the eventual anatomical distribution of these 
inclusions [40].
Weighting of primary determinants
Of the four primary determinants, molecular pa- 
thology has had the most profound impact over the 
last 25 years [20,54]. Should therefore this variable 
be regarded as the most fundamental? Classification 
based on molecular pathology, however, is often at 
variance with more traditional concepts based on 
anatomy. For example, AD and DLB are closely relat-
ed and overlap extensively in clinical and pathological 
features [20], but AD is a tauopathy and DLB a synu-
cleinopathy and therefore different at the molecu-
lar level. In addition, PSP is a tauopathy, but also an 
example of ‘atypical parkinsonism’ and therefore clin-
ically related to the synucleinopathies PD, MSA, and 
DLB [154]. Recent research has criticised the concen-
tration on ‘signature’ pathological lesions and their 
molecular determinants and has questioned whether 
this emphasis has been detrimental to the study of 
neurodegenerative disease as a  whole [39]. Hence, 
given current uncertainties regarding which variables 
are ‘important’ or ‘fundamental’, it is suggested that 
all four determinants should be given equal weight.
Application
An important practical question concerns what 
categories of anatomy, cells, molecules, and neuro-
degeneration should be used to define the descrip-
tive axes. The multiplicity of possible defining vari-
ables suggests the use of a multivariate data analysis 
method such as principal components analysis (PCA) 
[15,22]. Principal components analysis simplifies 
a description of cases based on multiple variables by 
selecting two or three axes which describe sources 
of maximum variation in the data, i.e., ‘the principal 
components’ (PC). Hence, a PCA enables the degree 
of similarity and dissimilarity between cases to be 
studied based on quantitative estimates of their 
neuropathological characteristics [15,22]. The result 
of a PCA is a scatter plot of cases in relation to the PC 
in which the distance between cases reflects their 
similarity or dissimilarity, based on the defining his-
tological features. Each PC therefore accounts for 
a proportion of the total variance in the data, PC1 
accounting for the greatest amount of the variance 
and remaining PCs for diminishing amounts of the 
remaining variance. Such a system appears to have 
the requisite multivariate geometry and simplici-
ty necessary to provide a  possible framework for 
describing neurodegenerative disease. The following 
examples are based on relatively small numbers of 
cases and a restricted range of descriptive variables 
to illustrate the methodology. 
Example 1: Investigating  
the relationships between  
closely related tauopathies
The objective was to investigate similarities and 
differences among 15 closely related tauopathy cases 
traditionally classified as AD, AGD, CBD, Guamanian 
Parkinson’s disease dementia complex (GPDC), or pri-
mary age-related tauopathy (PART). The defining vari-
ables include: (1) anatomy: frontal and temporal lobes 
and substantia nigra, (2) cells: neurons, astrocytes, 
oligodendrocytes, (3) molecules: tau, Aβ, and TDP-43, 
and (4) morphology: NCI, NT, GR, AT, GI, SP, EN, and 
Fig. 1. Principal components analysis of 15 tauo- 
pathy cases (AD – Alzheimer’s disease, AGD – argy-
rophilic grain disease, CBD – corticobasal degen-
eration, GPDC – Guamanian Parkinson’s disease 
dementia complex [GPDC], PART – primary age- 
related tauopathy) using variables derived from 
the four primary determinants. A plot of the cases 
in relation to the first two principal components 
(PC) 1 and 2 (Armstrong, unpublished data).
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vacuolation. A plot of the 15 cases in relation to the 
first two principal components is shown in Figure 1. 
Several features are evident from this plot. First, 
the majority of cases form a  single cluster towards 
the upper left of the plot, the two remaining cases 
(AD/AGD, CBD) being more atypical. Second, within 
the main cluster, there is no obvious clustering of cas-
es with similar co-pathology such as AD or TDP-43, 
although the two PART cases do occupy closely relat-
ed positions. Third, several neuropathological vari-
ables are correlated with the factor loadings of the 
cases on the PC but overall there is a general increase 
in tau pathology with increasingly negative loadings 
on PC1 and positive loadings on PC2. Hence, if a new 
tauopathy case were to be added to this analysis, it 
would be possible to determine: (1) from its location, 
whether the new case was a  typical or an atypical 
tauopathy, (2) the affinity of the new case relative 
to previous cases, and (3) the relative location of the 
case along a continuum of severity of tau pathology.
Example 2: Investigation of subtypes 
of FTLD-TDp
The second example is a  study of neuropatho-
logical heterogeneity within FTLD with TDP-43- 
immunoreactive pathology (FTLD-TDP). These cas-
es have a complex neuropathology comprising NCI, 
NII, GI, and DN. Four pathological subtypes of FTLD-
TDP have been proposed [37,114,150] based on the 
type and regional distribution of the various types 
of inclusion. Hence, type 1 cases (Mackenzie-type 2) 
are characterized by long DN in superficial cortical 
laminae with few or no NCI or NII, type 2 (Mackenzie- 
type 3) by numerous NCI in superficial and deep 
cortical laminae with infrequent DN and sparse or 
no NII, type 3 (Mackenzie-type 1) by pathology pre-
dominantly affecting the superficial cortical laminae 
with numerous NCI, DN and varying numbers of NII, 
and type 4 by numerous NII, and infrequent NCI 
and DN especially in neocortical areas. The defin-
ing variables were: (1) anatomy: frontal and tem-
poral lobes, (2) cells: neurons and oligodendroglia, 
(3) molecules: TDP-43, and (4) neurodegeneration: 
NCI, NII, DN, and GI. Hence, quantitative estimates 
of density of TDP-43-immunoreactive neuronal and 
glial inclusions were made in frontal and tempo-
ral regions of 94 cases of FTLD-TDP [22]. A PCA of 
the data is shown in Figure 2 and shows that cases 
representing the four subtypes exhibit considerable 
overlap, subtypes 1 and 4 being the most distinctive 
and located towards the bottom and top of the plot 
respectively. Cases of subtype 2 and 3 were less dis-
tinct, with a greater degree of overlap. Hence, new 
cases could be added to the analysis over time and 
their location relative to PC1 and PC2, and therefore 
to all previous cases, established. Location of a new 
case would suggest to which subtype the case may 
belong. Hence, in Figure 2, new case A  would be 
most likely to be an example of subtype 1 and case B 
of subtype 4. New cases C and D are more difficult to 
classify, although it is probable that they have more 
affinity with subtypes 2 and 3. 
Further applications
More extensive applications of the methodology 
could include all cases of neurodegenerative disease 
from a single neuropathological centre and ultimate-
ly from several contributing centres. A major prob-
lem in attempting to apply this approach on a larger 
scale, however, is the lack of comparative quanti-
tative data of sufficient scope, detail, quality, and 
consistency to define all possible cases. Most quan-
Fig. 2. Principal components analysis of 94 cases 
of frontotemporal lobar degeneration with TDP 
proteinopathy (FTLD-TDP) based on the densi-
ties of TDP-43 immunoreactive neuronal and 
glial inclusions in frontal and temporal cortex. 
Identified on the plot are the subtypes of disease 
based on the system of Cairns et al. (2007). Cas-
es marked A, B, C, D are new cases added to the 
existing plot (data from Armstrong et al. 2010).
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titative studies of a  disorder quantify only signa-
ture pathological lesions [11], while others confine 
observations to a  restricted number of anatomical 
regions or cell types, whereas all aspects of anato-
my, cells, molecules, and morphology would need to 
be measured in each case. Nevertheless, the recent 
detailed comparative study of a large number of cas-
es of ten neurodegenerative diseases, albeit using 
semi-quantitative data [25], demonstrates that it is 
feasible to collect comparative data across a  large 
number of cases and disorders, enabling a descrip-
tive system to be developed based on the four pri-
mary determinants.
Conclusions
This review proposes that four primary deter-
minants could be used as the basis of a system to 
describe the neuropathology of neurodegenerative 
disease and which can take into account disease 
heterogeneity, overlap, and the presence of multi-
ple pathologies. Such an approach has a number of 
advantages. First, it could describe all cases of neu-
rodegenerative disease, not just those that may fit 
more traditional concepts. Second, it would empha-
sise the continuous nature of neurodegenerative 
disease by incorporating disease heterogeneity and 
overlap to their true extent [8,19]. Third, it would 
remove the necessity to classify new cases within an 
existing system, especially those which exhibit more 
complex multiple pathologies, as each case would 
be regarded as unique and would be located within 
a space defined by the primary determinants. Fourth, 
it potentially reveals the similarities and differences 
between cases included in the analysis, emphasis-
ing that common pathological mechanisms may be 
involved in different disorders. A major limiting fac-
tor in applying such a system on a large scale, how-
ever, is the current lack of detailed quantitative data 
of sufficient quality across cases and disorders [25].
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